L ow-density lipoprotein (LDL) cholesterol (LDL-C), high-density lipoprotein (HDL) cholesterol (HDL-C), and triglycerides are the standard blood lipid-related laboratory measurements used for cardiovascular disease (CVD) risk assessment and management, yet a significant burden of CVD risk is not revealed by these standard blood lipid measurements. Recent data raise concerns about the standardization of LDL-C, whether calculated from the Friedewald Background-Cardiovascular disease (CVD) can occur in individuals with low low-density lipoprotein (LDL) cholesterol (LDL-C). We investigated whether detailed measures of LDL subfractions and other lipoproteins can be used to assess CVD risk in a population with both low LDL-C and high C-reactive protein who were randomized to high-intensity statin or placebo.
L ow-density lipoprotein (LDL) cholesterol (LDL-C), high-density lipoprotein (HDL) cholesterol (HDL-C), and triglycerides are the standard blood lipid-related laboratory measurements used for cardiovascular disease (CVD) risk assessment and management, yet a significant burden of CVD risk is not revealed by these standard blood lipid measurements. Recent data raise concerns about the standardization of LDL-C, whether calculated from the Friedewald equation or measured directly, with significant variability and discrepant clinical results noted among various methods for LDL-C determination. [1] [2] [3] Moreover, a sizeable proportion of CVD events occur in individuals who have LDL-C levels that are not traditionally considered to be at elevated CVD risk. 4 It has been hypothesized that some of this increased risk is due to high particle concentrations (numbers) of LDL (LDL-p), other atherogenic lipoproteins (very-low-density lipoprotein [VLDL] particles and intermediate-density lipoprotein [IDL] ), or their subfractions and that risk resulting from these particles may not be reflected by levels of LDL-C, triglycerides, or estimated non−HDL-C. 5 Thus, a more direct laboratory determination of lipoprotein particle number may reveal clinically relevant findings masked by the standard estimation of lipoprotein cholesterol concentration. Atherogenic lipoproteins (VLDL, IDL, LDL), regardless of their size, each contain 1 apolipoprotein (apo) B molecule per particle; hence, apoB level is a measure of total atherogenic lipoprotein concentration. 5 On the other hand, HDL-C determination involves estimation based on either masking or removing apoB-containing particles to measure HDL-C. 6 The estimation of HDL-C would also affect the estimated non−HDL-C.
The present study addresses the potential role of a novel laboratory method (ion mobility [IM] ) that directly determines lipoprotein number across the entire lipoprotein spectrum (VLDL, IDL, LDL, and HDL) independently of the cholesterol composition of the particles. IM determines particle number after separating lipoprotein particles by size using gas-phase electrophoresis and directly counting the size-separated particles. To date, IM lipoprotein subfractions and CVD events have been evaluated in the Malmö Diet and Cancer Study cohort of middle-aged Europeans, finding that, among individuals not classified into a statin benefit group, LDL-p determined by IM was associated with incident coronary events after adjustment for standard lipids. 7, 8 It is uncertain whether these more specific measures of particle concentration and size for LDL and other lipoproteins are related to CVD risk when LDL-C levels are low, although risk tracks better with particle concentration than cholesterol when these measures disagree. 9 Furthermore, it is unknown whether lipoprotein subfractions contribute to the residual risk of CVD during high-intensity statin therapy. This is important because variation in lipoprotein subfractions may influence CVD risk and may be selectively manipulated. The newly discovered function of the SORT1 gene exemplifies the biological and potential therapeutic relevance of selective regulatory pathways for lipoprotein subfractions: The SORT1 gene modulates levels of hepatic apoB secretion and uptake, preferentially altering plasma levels of small and very small LDL subfractions, and the risk of myocardial infarction. 10, 11 Therefore, in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) cohort, which is characterized by low LDL-C (<130 mg/dL) and triglycerides <500 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP), we investigated whether IM-measured lipoproteins or their subfractions predict CVD events after allocation to placebo or high-intensity statin therapy.
Methods

Study Population
The JUPITER design has been previously published (http://www. clinicaltrials.gov, NCT00239681). 12 Asymptomatic individuals (women ≥60 years of age, men ≥50 years of age) without prior history of CVD were randomized into the trial if they had LDL-C <130 mg/dL and hsCRP ≥2.0 mg/L. The JUPITER exclusion criteria included triglycerides ≥500 mg/dL, current use of hormone therapy, and previous or current use of lipid-lowering therapy or immunosuppressant agents. The trial protocol stipulated a baseline and 12-month visit at which time blood was drawn for standard assays at a central laboratory as described below. Remaining blood samples were sent to the Clinical Coordinating Center at the Brigham and Women's Hospital (Boston, MA) and stored in liquid nitrogen. Four to 5 years after trial completion, IM measurements were performed on 11 277 of the 13 658 individuals with a stored baseline sample for whom sufficient sample remained. For the present analysis, we additionally excluded individuals who were missing any baseline standard lipid or apolipoprotein measurements (n=91), resulting in a total sample size of 11 186. Of these, 9430 had both baseline and 12-month IM measurements.
Laboratory Measurements
Standard lipids, apolipoproteins, hsCRP, and glucose measurements were performed in a central laboratory on fasting blood samples as previously described (Methods in the online-only Data Supplement). 13 Consistent with previous JUPITER analyses, on-treatment concentrations were defined as values obtained after 1 year of randomized treatment.
11-14 IM lipoproteins were measured at Quest Diagnostics Nichols Institute (San Juan Capistrano, CA; see Methods and Table I in the online-only Data Supplement).
Outcomes
On March 30, 2008 , the Independent Data and Safety Monitoring Board terminated the JUPITER trial early on determination that the accumulated evidence from the trial and other sources constituted proof beyond a reasonable doubt that rosuvastatin was indicated for a specified group of participants (after a 1.9-year median follow-up; maximal follow-up, 5.0 years). 12 The primary end point of the trial was a composite CVD end point, defined as myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death. We also prespecified examining the expanded secondary end point of CVD or all-cause death, as done previously.
14 Reported end points were adjudicated by an independent end-point committee blinded to randomized treatment.
Statistical Analyses
Statistical analyses were performed with STATA version 10.1. Change from baseline to 1-year levels was depicted in box plots and compared by use of the Wilcoxon signed-rank test. The Wilcoxon rank-sum test was used to test whether change from baseline to 1-year levels differed according to treatment group allocation.
Associations with outcomes were performed according to the treatment to which participants were randomized. Exposure time was calculated as the time from randomization to the occurrence of the primary end point event, date of death, last visit, withdrawal, loss to followup, or March 30, 2008 , whichever came first. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), with robust standard errors reported. Biomarkers were modeled as continuous variables with results reported per standard deviation of the baseline distribution and per tertiles, consistent with prior JUPITER analyses.
14 Analyses were adjusted for age, sex, race, smoking status, family history of premature coronary disease, body mass index, systolic blood pressure, fasting glucose, and the natural logarithm of hsCRP. Some analyses also adjusted for LDL-C, HDL-C, and natural logarithm of triglycerides to determine whether the subfractions were independently associated with CVD risk after accounting for their correlation with standard lipids. Each IM subfraction was assessed in a separate model unless otherwise noted. We fitted additional models that evaluated the incremental prognostic value of the panel of IM subfractions by entering them as a set 15, 16 added to a base model with the established risk factors, including standard lipids. Next, a parsimonious set of subfractions was selected with the use of backward elimination (retention threshold, P<0.05), forcing the established risk factors (including standard lipids) in the model. A multivariable P value for the full and parsimonious set was obtained from the likelihood-ratio test comparing the base model plus subfractions with the base model only. Model discrimination was examined using the c index, 17 a generalization of the area under the receiver-operating characteristic curve that is applicable to survival data. The likelihood-ratio χ 2 statistic was used to evaluate for treatment-by-lipoprotein interaction. P values were 2 tailed.
Results
Baseline characteristics for individuals with IM measurements were similar to those of the overall JUPITER population 12 except that the present study had more whites (Table II in Table  1 ). Profiles of IM-measured apoB-containing lipoproteins in JUPITER participants at baseline and after 1 year of rosuvastatin therapy are shown in Figure 1 . In the rosuvastatin arm, there were smaller relative reductions of non-HDL particles (non−HDL-p; 29.5%) and LDL-p (27.8%) compared with non−HDL-C or apoB. The larger LDL subfractions were reduced more by rosuvastatin (23-37%) than the smaller ones (<8%), resulting in a shift of the predominant LDL peak to a smaller particle diameter (Table 1 and Figure I in the onlineonly Data Supplement). For HDL measures, rosuvastatin resulted in small increases in HDL-C (6.4%) and apoA-I (1.7%) but small decreases in IM HDL-p and its subfractions.
Baseline Measures and Incident CVD Events
During a median follow-up of 1.9 years (maximum, 5.0 years), the 11 186 participants (5600 placebo/5586 rosuvastatin) experienced 307 first primary CVD events (199 placebo/108 rosuvastatin) and 522 combined CVD and all-cause death events (322 placebo/200 rosuvastatin). In the placebo-allocated arm ( Of the VLDL subfractions, the triglyceride-enriched large and medium subfractions were associated with CVD, similar to chemically measured triglycerides. Within the IDL subfractions, only the smaller subfraction showed a trend toward association, which was strengthened and became statistically significant (HR, 1.24; 95% CI, 1.09-1.40; P=0.001) after additional adjustment for LDL-C, HDL-C, and triglycerides. None of the HDL subfractions were associated with CVD.
Furthermore, LDL subfractions were associated with CVD, but associations differed according to the sizes of the LDL particles and adjustment for standard lipids (Table 2 and  Table IV in the online-only Data Supplement). Before such adjustment, associations were noted for all but the largest LDL (LDL-I and -IIa) subfractions. However, as was also seen with the adjacent small IDL subfraction, after further adjustment for lipids (in particular triglycerides and HDL-C), subfractions LDL-I through -IIIa ( When examined in relation to the expanded secondary end point of CVD and all-cause death that occurred in the placebo group (n events/N=322/5600; 
Residual Risk During High-Intensity Statin Therapy
Among rosuvastatin-allocated individuals with complete ontreatment data, significant associations were noted for ontreatment LDL-C, non−HDL-C, and apoB with both residual risk of CVD events (n events/N: 73/4597; Table 3 and Tables  IV and VI and Figure II in the online-only Data Supplement) and with residual risk of the expanded end point of CVD and all-cause death (n events/N, 108/4597). Although none of the IM-measured lipoprotein fractions were significantly associated with residual risk of the primary end point in the subgroup of rosuvastatin-treated participants, effect estimates were consistent with the statistically significant associations seen with the expanded end point of CVD and all-cause death, which included a greater number of events. In particular, increased residual risk was noted for non−HDL-p, VLDL particles (medium and small subfractions), IDL particles and subfractions, and LDL-p (medium to large subfractions). Tests for treatment-by-lipoprotein interaction yielded significant differences for both the primary and expanded end points for small VLDL particles, IDL particles and subfractions, and large LDL-p subfractions. 
Incremental Prognostic Value of the Set of IM Subfractions
Discussion
In the JUPITER trial population, recruited on the basis of low LDL-C and elevated hsCRP, baseline LDL-C was not associated with incident CVD. In contrast, incident CVD was associated with a greater atherogenic particle burden, as estimated by non−HDL-C or measured by an immunoassay for apoB or the IM method for non−HDL-p and LDL-p and select subfractions (primarily large and medium VLDL and medium to very small LDL). During high-intensity statin therapy, on-treatment apoB, non−HDL-C, and LDL-C were associated with residual risk. However, the pattern of lipoprotein subfractions that was associated with residual risk differed from the baseline risk, with a shift toward more prominent residual risk associations for smaller VLDL and larger LDL subfractions. These results indicate that CVD risk can be increased despite low LDL-C as a result of a higher number of atherogenic particles within the VLDL-LDL particle spectrum. This study also suggests that on-treatment levels of atherogenic particles can contribute to residual risk during statin therapy, potentially indicating inadequate statin efficacy. Finally, risk prediction was improved by adding a set of IM subfractions to models with established risk factors, including standard lipids, BMI, and hsCRP. The present findings are consistent with the growing literature from multiple population-based studies of mostly †P values from the Wilcoxon rank-sum test comparing the change among the rosuvastatin group with the change among the placebo group were <0.01 for all except for LDL-IVc and total HDL-p (P=0.11 and 0.37, respectively). All changes were in the direction of rosuvastatin>placebo except for LDL-IVb.
‡100×(year 1−baseline)/baseline. statin-naive individuals in whom CVD risk tracked with discordantly elevated particle-based measures when LDL-C was low. 8, 9, 18, 19 The present study, conducted in a multinational clinical trial, adds to the only other prospective analysis of IM lipoproteins in relation to CVD events, which also found risk to be associated with non−HDL-C and IM non−HDL-p and LDL-p. 7 Furthermore, in the present study, adjusting for LDL-C, HDL-C, and triglycerides did not affect the association of apoB or IM non−HDL-p or LDL-p with CVD, indicating that the increased risk is attributable more to atherogenic particle concentrations than to the load of cholesterol or triglycerides of the particles.
Rosuvastatin therapy resulted in reductions across the spectrum of atherogenic apoB-containing particles, although to a lesser degree than was seen for LDL-C. The most pronounced reductions were seen in the larger atherogenic particles, with a smaller effect on the smaller particles, resulting in a slight shift in the LDL-p distribution toward a smaller size. Prior studies that assessed the effects of statins on lipoprotein subfractions *Per 1-SD increment in the lipid or lipoprotein variable, adjusted for age, sex, race, smoking, family history, body mass index, systolic blood pressure, glucose, and natural log-transformed high-sensitivity C-reactive protein.
†Variables that met statistical significance (P<0.05) in models that included LDL-C, HDL-C, natural log transformed triglycerides, age, sex, race, smoking, family history, body mass index, systolic blood pressure, glucose, and natural log-transformed high-sensitivity C-reactive protein.
by guest on April 20, 2017 http://circ.ahajournals.org/ Downloaded from December 8, 2015 had fewer participants and used different laboratory methods and various statins. These studies had mixed results, with most studies finding no change in peak or average LDL size [20] [21] [22] [23] [24] [25] but others finding an increase 26 or a slight decrease. 27 The preferential reduction in larger, cholesterol-rich LDL particles in the present study is consistent, however, with previous findings for other statins, 28 and this effect likely contributed to the relatively greater reduction in LDL-C versus apoB and other measures of LDL-p concentration.
Higher levels of LDL-C, non−HDL-C, or apoB during statin therapy were associated with a higher residual risk of CVD, consistent with previous reports. 14, 29 Notably, this risk was related to on-treatment levels of the LDL subfractions (LDL-I to -IIIa) that were predominantly lowered by rosuvastatin. Residual risk was also associated with on-treatment levels of smaller VLDL and large IDL, which may represent remnants of triglyceride-rich lipoproteins that were also insufficiently reduced by rosuvastatin. Therefore, these lipoprotein fractions may be targeted by more aggressive lifestyle therapies or potentially with newer pharmacological agents if they are proven to be efficacious in outcomes-driven clinical trials.
Interestingly, although levels of larger LDL subfractions were not related to increased CVD risk within the placeboallocated arm in risk factor-adjusted models, a significant association with risk emerged after further adjustment for triglycerides and HDL-C, whereas the risk associated with the smaller LDL subfractions diminished after this adjustment (except for LDL-IVc). The attenuation of the association of the larger LDL subfractions with CVD when triglycerides and HDL-C were not taken into account suggests that triglycerides and HDL-C may negatively confound this association; conversely, the strengthening of the association of the smaller LDL subfractions with CVD when triglycerides and HDL-C were not taken into account suggests that triglycerides and HDL-C may positively confound this association. 30 These observations are consistent with results from another statin clinical trial in which large, predominant LDL peak size (measured by gel electrophoresis) was associated with increased recurrent CVD events, an association that was strengthened after adjustment for standard lipids in the placebo group and not observed in the statin group. 31 Finally, unlike the Malmö study, we found that IM-measured HDL-p was not statistically significantly associated with CVD risk. 7 This also contrasts with our prior finding in JUPITER that HDL-p as measured by nuclear magnetic resonance was inversely associated with CVD among both the placebo-and rosuvastatin-allocated arms. 32 This could relate to differences in the lipoprotein isolation method for the IM method that were introduced since the Malmö study was performed or to differences between the IM and nuclear magnetic resonance methods. The modified lipoprotein isolation method used in the present study avoided ultracentrifugation, which may have resulted in the measurement of other proteins in the size range for HDL-p that otherwise would have been sedimented in the centrifugation process used to prepare samples for IM measurements in the Malmö study (see Methods in the online-only Data Supplement). Alternatively, it could be that the HDL particles detected by IM may be more protein rich and less lipid loaded compared with the nuclear magnetic resonance HDL-p measurement. Moreover, in a population such as JUPITER that is enriched for individuals with chronic inflammation, some HDL particles may be dysfunctional, which may be more closely related to protein-rich HDL (potentially better measured by the IM method) than lipid-rich HDL (potentially better measured by the nuclear magnetic resonance method). Indeed, although it was not statistically significant, the direction of effect for the top versus bottom tertile of small HDL-p was positively associated with CVD in both treatment arms, as was seen in other studies with the small lipid-poor pre-β1 HDL, possibly as a result of impaired cholesterol efflux or esterification. 33 This finding merits further investigation in future studies.
Strengths and Limitations
Strengths of this study include the prospective analysis from the JUPITER trial of the effects of high-intensity statin therapy versus placebo on a wide variety of standard lipids, apolipoproteins, and the novel IM lipoprotein subfractions, measured both at baseline and on-treatment, and the assessment of associations with incident CVD events before and after random allocation to statin therapy versus placebo. The present study also has potential limitations. Median duration of follow-up in JUPITER was 1.9 years (maximum, 5.0 years) owing to early termination of the trial for benefit, and associations with events occurring over a longer term could not be assessed. The absolute number of CVD events was low, and the results may not apply to other population groups. The results may not apply to a general population because JUPITER excluded individuals with known CVD, diabetes mellitus, or high triglycerides and those who did not meet entry criteria for LDL-C and hsCRP. Regression coefficients for some of the measures may depend on their study-specific variability, which is also influenced by the trial eligibility criteria. We performed multiple comparisons, which increases the chance of a type I error. However, lipids and lipoproteins are correlated, and we interpreted the results, emphasizing the magnitude of effects and the consistency with prior experimental and epidemiological studies. Although the enhanced resolution of lipoprotein subfractions obtained by IM sheds new light on the relationship of these particles to CVD events, the role of other unmeasured factors should not be excluded. Finally, we are unable to rule out possible association for some of the biomarkers with residual risk of the primary end point of CVD because of the relatively small number of primary CVD events in the rosuvastatin arm. Our results should be viewed as hypothesis generating and require further evaluation in other studies.
Conclusions
Despite the low levels of LDL-C among JUPITER participants, first CVD events were associated with higher baseline levels of atherogenic particles, as assessed by non−HDL-C, apoB, and IM non−HDL-p, LDL-p, and select subfractions (primarily large and medium VLDL and medium to very small LDL). During high-intensity statin therapy, residual risk was influenced by on-treatment levels of atherogenic particles and LDL-C. However, the pattern of lipoprotein subfractions that was associated with residual risk differed from that seen with baseline risk, with a shift toward more prominent residual risk associations for smaller VLDL and larger LDL subfractions, which may indicate inadequacy of the statin response and the potential for targeting these particles by additional therapies for further reducing residual CVD risk.
CLINICAL PERSPECTIVE
A large proportion of cardiovascular events occur among individuals who have normal or even low low-density lipoprotein (LDL) cholesterol. Some of these events may be related to high particle concentrations (numbers) of LDL or other atherogenic lipoproteins (such as very-low-density lipoprotein and intermediate-density lipoprotein). These atherogenic lipoproteins each contain 1 apolipoprotein B molecule, but they represent a heterogeneous group of particles that span a spectrum of size, density, and cholesterol or triglyceride composition. It is unknown whether lipoprotein subfractions contribute to cardiovascular risk among statin-naive individuals or after statin initiation. The present study evaluated a novel method (ion mobility) that directly quantifies lipoprotein particles across the entire lipoprotein spectrum. With the use of ion mobility, baseline and on-treatment lipoprotein subfractions were measured in 11 186 participants in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, a cohort characterized by low LDL cholesterol but elevated high-sensitivity C-reactive protein. Incident cardiovascular events were not associated with baseline LDL cholesterol but were associated with higher baseline levels of atherogenic particles as assessed by non-high-density lipoprotein cholesterol, apolipoprotein B, and ion mobility-measured non-high-density lipoprotein particles or LDL particles and by select subfractions (primarily large and medium very-low-density lipoprotein and medium to very small LDL). During high-intensity statin therapy, the pattern of lipoprotein subfractions that was associated with residual cardiovascular risk differed from that seen at baseline, with a shift toward more prominent associations for smaller very-low-density lipoprotein and larger LDL subfractions. This may indicate inadequacy of the statin response and the potential for targeting these particles by additional therapies for further reducing risk among statin-treated individuals.
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SUPPLEMENTAL MATERIAL
2
Supplemental Methods
Laboratory Measurements
Assessment for total cholesterol used an enzymatic procedure (cholesterol esterase) with a colorimetric endpoint. Triglycerides were measured with an enzymatic hydrolysis procedure to obtain a colorimetric endpoint triglyceride value. HDL-c was measured in the resulting supernatant after heparin-manganese precipitation of apolipoprotein B-containing proteins.
LDL-c was calculated by the Friedewald equation when triglycerides were <400 mg/dL, 1 and measured by ultracentrifugation when triglycerides were ≥400 mg/dL. Concentrations of whole plasma apoB and A-I were measured by immunonephelometry using a Behring nephelometeric assay (Marburg, Germany). A high-sensitivity assay (Behring Nephelometer) was used for measurement of hsCRP.
Prior to ion mobility (IM) fractionation, lipoproteins were isolated by dextran sulfate precipitation. Plasma was treated with 17% ethanol which removed >97% of fibrinogen, and lipoproteins were then precipited with dextran sulfate (2 mg/mL) and calcium (0.15 M).
Precipitated lipoproteins were harvested on paramagnetic particles, washed to remove free salt and proteins and then resuspended in 25 mM ammonium acetate foranalysis by ion mobility.
This method recovered all measureable apoB (105%), apoA-I (96%) and total cholesterol (103%). Removal of plasma proteins was assessed by the following proteins (final concentration remaining after extraction compared with original serum concentration): IgG (3%), albumin (<4%), transferrin (0%). This new isolation procedure has excellent recovery of the lipoprotein particles based on the apolipoprotein and total cholesterol recoveries. The median apoA-I/HDLp concentration (mM) ratio was 1.4 (Table 1 and Supplemental Tables 1 and 2 ) for apoA-I 3 molecular weight 28.07 kDa, which is similar to the ratio (1.6) determined by nuclear magnetic resonance spectroscopy in the same population.
2
Following isolation, the lipoproteins were fractionated and quantitated in a single scan using gas-phase electrophoresis (ion mobility) as previously described. 3 The intra-assay variation was <0.8% for LDL peak particle size and <10% for HDL-p, LDL-p, IDL-p, and VLDL-p. Inter-assay variation was <0.7% for the LDL peak particle size and <13% for HDL-p, LDL-p, IDL-p and VLDL-p. Supplemental Table 1 shows the lipoprotein subfractions, their size ranges, and nomenclature. 
